H. Lundbeck A/S hereby reports transactions made by executives and persons and
legal entities closely associated to them with shares in H. Lundbeck A/S and
linked securities, cf. section 28a of the Danish Securities Trading Act.
The list is based on reports received by H. Lundbeck A/S from the company's
executives today or yesterday.
Name: Anders Gersel Pedersen
Job position of the Executive Vice President &
executive: Head of Research & Development
ID code (ISIN code): DK 0010287234
Description of the Share
security:
Nature of the transaction: Transferred as part of Lundbeck’s Long Term
Incentive Program for Executive Management
Date of trading: 23 May 2012
Market on which the Nasdaq OMX Copenhagen
trading was effected:
Number of traded 33,583 shares
securities:
Persons or entities under an obligation to report are defined as members of the
Executive Management and the Supervisory Board of H. Lundbeck A/S and
persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
-- spouse or cohabitant
-- children below the age of 18
-- legal entities in which the insider has a controlling influence
The content of this release will have no influence on the Lundbeck Group’s
financial expectations for 2012.
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Chief Specialist, Head of Investor Relations Media Relations Manager
palo@lundbeck.com mavk@lundbeck.com
+45 36 43 24 26 +45 36 43 28 51
Magnus Thorstholm Jensen Simon Mehl Augustesen
Investor Relations Officer International Media Specialist
matj@lundbeck.com smeh@lundbeck.com
+45 36 43 38 16 +45 36 43 49 80
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from brain disorders. For this purpose, Lundbeck is engaged in the research,
development, production, marketing and sale of pharmaceuticals across the
world. The company’s products are targeted at disorders such as depression and
anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and
Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the
world’s leading pharmaceutical companies working with brain disorders. In 2011,
the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or
USD 3.0 billion). For more information, please visit www.lundbeck.com.